Hematologic Malignancy
Myeloid Leukemia
CI-CAN-00001251Explore in graph →
Hematologic862 active trials22 approved drugs599 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001251Explore in graph →
Clinical trials
3,530 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (619)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07238712 | Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor(APTBCy) | recruiting | Phase 2 | 60 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT06532552 | Comparison of VA (Venetoclax, Azacitidine), VACl (VA, Cladribine), VACh (VA, Chidamide), and Alternating VACl/VACh in Newly Diagnosed Acute Myeloid Leukemia | recruiting | Phase 2 | 172 | The First Affiliated Hospital of Soochow University |
| 1 |
| Nov 19, 2025 |
| clinicaltrials |
| NCT06451861 | Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML | recruiting | Phase 2 | 240 | Guangdong Provincial People's HospitalOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT02143830 | HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy(RAFA) | recruiting | Phase 2 | 70 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT05986240 | Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML | recruiting | Phase 1 | 38 | Montefiore Medical CenterOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT06472128 | Novel Digital Application for Patients With Acute Leukemia(NAVIGATE) | recruiting | N/A | 200 | Massachusetts General HospitalOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT04260022 | Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL | recruiting | Phase 1 | 242 | Ascentage Pharma Group Inc.INDUSTRY | 2 | Nov 5, 2025 | clinicaltrials |
| NCT05031897 | Two Step Haplo With Radiation Conditioning | recruiting | Phase 2 | 63 | Thomas Jefferson UniversityOTHER | 1 | Oct 30, 2025 | clinicaltrials |
| NCT04678401 | IS-free Treg HaploHCT | recruiting | Phase 1 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 20, 2025 | clinicaltrials |
| NCT02508038 | Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors | recruiting | Phase 1 | 22 | University of Wisconsin, MadisonOTHER | 1 | Oct 16, 2025 | clinicaltrials |
| NCT04986657 | Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS | recruiting | N/A | 325 | Washington University School of MedicineOTHER | 1 | Oct 16, 2025 | clinicaltrials |
| NCT04777916 | Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)(ALFAPPP) | recruiting | — | 5,000 | Acute Leukemia French AssociationOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT07205523 | High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)(HALO-SCT) | recruiting | — | 1,000 | Yigeng Cao,MD,PhDOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT05211570 | AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia | recruiting | Phase 1 / Phase 2 | 78 | AB ScienceINDUSTRY | 4 | Oct 2, 2025 | clinicaltrials |
| NCT06307054 | CLL-1 CAR-NK Cells for Relapsed/Refractory AML | recruiting | Phase 1 | 24 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT07198867 | A Study of A-CAR028 Treatment in Subjects With Relapsed or Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 20 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT06501196 | A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome | recruiting | Phase 1 | 170 | BlossomHill TherapeuticsINDUSTRY | 1 | Sep 24, 2025 | clinicaltrials |
| NCT01311258 | Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome(MRD) | recruiting | — | 400 | University of RochesterOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT05305859 | Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML | recruiting | Phase 2 | 30 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT07165535 | Quality of Life and Care Organization of Patients With Chronic Myeloid Leukemia in the Lombardy Hematology Network | recruiting | — | 2,000 | University of Milano BicoccaOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT07162116 | A Study to Evaluate the Effect of XY0206 on the QTc Interval in Chinese Healthy Participants(XY0206-CQT) | recruiting | Phase 1 | 45 | Shijiazhuang Yiling Pharmaceutical Co. LtdINDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT04385290 | Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)(MOSAIC) | recruiting | Phase 1 / Phase 2 | 214 | Technische Universität DresdenOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT07109518 | uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies | recruiting | Phase 1 | 12 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT07144020 | Donor Derived CD117 CAR-T Cells in the Treatment of R/R Acute Myeloid Leukemia | recruiting | Early Phase 1 | 50 | Zhejiang UniversityOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT03850574 | Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia(TUSCANY) | recruiting | Phase 1 / Phase 2 | 240 | Aptose Biosciences Inc.INDUSTRY | 6 | Aug 26, 2025 | clinicaltrials |
| NCT07016165 | Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Malignancies | recruiting | Phase 4 | 120 | Gadjah Mada UniversityOTHER | 1 | Aug 22, 2025 | clinicaltrials |
| NCT06378437 | A Study of GLB-001 in Patients With Myeloid Malignancies | recruiting | Phase 1 | 108 | Hangzhou GluBio Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 19, 2025 | clinicaltrials |
| NCT07075016 | Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy(EVOLVE 1) | recruiting | Phase 3 | 227 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 16 | Aug 19, 2025 | clinicaltrials |
| NCT07126782 | The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT | recruiting | Early Phase 1 | 10 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT06387069 | A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia | recruiting | Phase 3 | 316 | HutchmedINDUSTRY | 1 | Aug 14, 2025 | clinicaltrials |
| NCT06513273 | Observational Study on the Outcome of AML Patients Treated With New Drugs in Real-life (BoxTrial)(Box) | recruiting | — | 397 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT07117422 | Venetoclax-Decitabine in Untreated Elderly/Unfit AML | recruiting | N/A | 39 | The Second Hospital of Hebei Medical UniversityOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT07023588 | Study on Optimizing the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residual Disease | recruiting | Phase 2 | 70 | Yehui TanOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT05909501 | Assessment of Geriatric Evaluations Impact on New AML Guidance(AGE-ING) | recruiting | — | 100 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT07108530 | Efficacy of Integrated Induction-Consolidation Chemotherapy and Transplantation for Adult Acute Myeloid Leukemia: Multicenter Study | recruiting | Phase 2 | 50 | Shanxi Bethune HospitalOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT07106749 | CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies | recruiting | Phase 1 | 12 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT06386302 | Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia | recruiting | N/A | 184 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 3, 2025 | clinicaltrials |
| NCT05659732 | A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer | recruiting | Phase 1 | 32 | PharmaEngineINDUSTRY | 2 | Jul 31, 2025 | clinicaltrials |
| NCT06458257 | The Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Newly Diagnosed High-relapse-risk CEBPA Mutant Acute Myeloid Leukemia | recruiting | — | 50 | Ruijin HospitalOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT07078591 | Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML | recruiting | Phase 2 | 50 | Beijing 302 HospitalOTHER | 1 | Jul 28, 2025 | clinicaltrials |
| NCT05237258 | Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia(SCOPE-L) | recruiting | N/A | 2,300 | Massachusetts General HospitalOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05703542 | BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome | recruiting | Phase 1 | 24 | Eric Stephen Winer, MDOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT07028086 | VAM in Secondary AML, AML With Extramedullary Involvement, and Myeloid Sarcoma | recruiting | Phase 2 | 48 | Ruijin HospitalOTHER | 1 | Jul 9, 2025 | clinicaltrials |
| NCT06409936 | PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML(PEARL) | recruiting | Phase 2 | 160 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT06787144 | ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants(CML) | recruiting | Phase 1 | 21 | Enliven TherapeuticsINDUSTRY | 1 | Jul 1, 2025 | clinicaltrials |
| NCT06199557 | A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML/HR-MDS Patients(HUVAMER) | recruiting | Phase 1 / Phase 2 | 48 | Haukeland University HospitalOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT07036250 | Clinical Study of U32 in Patients With Acute Myeloid Leukemia | recruiting | Phase 1 / Phase 2 | 20 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | Jun 25, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Nov 20, 2025source: clinicaltrials